Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been assigned an average recommendation of “Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $22.40.
Several brokerages have weighed in on VNDA. Seaport Global Securities reissued a “buy” rating and set a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, February 28th. BidaskClub raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, February 21st. Oppenheimer set a $27.00 price target on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 5th. ValuEngine raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 12th. Finally, Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 10th.
Get Vanda Pharmaceuticals alerts:
Shares of Vanda Pharmaceuticals opened at $17.15 on Thursday, Marketbeat reports. The firm has a market capitalization of $875.46 million, a PE ratio of -49.00 and a beta of 1.12. Vanda Pharmaceuticals has a 52-week low of $16.80 and a 52-week high of $17.05.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, May 2nd. The biopharmaceutical company reported $0.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.23. The business had revenue of $43.59 million during the quarter, compared to analysts’ expectations of $43.30 million. Vanda Pharmaceuticals had a negative net margin of 2.84% and a negative return on equity of 3.06%. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.11) EPS. analysts forecast that Vanda Pharmaceuticals will post -0.05 earnings per share for the current fiscal year.
In related news, insider Mihael Hristos Polymeropoulos sold 60,966 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $18.72, for a total value of $1,141,283.52. Following the completion of the transaction, the insider now directly owns 1,243,838 shares in the company, valued at approximately $23,284,647.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Gunther Birznieks sold 8,525 shares of the stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $18.72, for a total transaction of $159,588.00. Following the completion of the transaction, the senior vice president now owns 148,366 shares of the company’s stock, valued at $2,777,411.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 78,023 shares of company stock valued at $1,460,591. Corporate insiders own 7.60% of the company’s stock.
Several institutional investors have recently modified their holdings of VNDA. Schwab Charles Investment Management Inc. increased its stake in Vanda Pharmaceuticals by 2.0% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 482,012 shares of the biopharmaceutical company’s stock valued at $7,327,000 after purchasing an additional 9,496 shares in the last quarter. Strs Ohio increased its stake in Vanda Pharmaceuticals by 27.4% during the 4th quarter. Strs Ohio now owns 56,200 shares of the biopharmaceutical company’s stock valued at $854,000 after purchasing an additional 12,100 shares in the last quarter. Birchview Capital LP increased its stake in Vanda Pharmaceuticals by 29.4% during the 4th quarter. Birchview Capital LP now owns 88,000 shares of the biopharmaceutical company’s stock valued at $1,338,000 after purchasing an additional 20,000 shares in the last quarter. Cadence Capital Management LLC increased its stake in Vanda Pharmaceuticals by 74.2% during the 4th quarter. Cadence Capital Management LLC now owns 109,074 shares of the biopharmaceutical company’s stock valued at $1,658,000 after purchasing an additional 46,468 shares in the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in Vanda Pharmaceuticals during the 4th quarter valued at about $209,000. Institutional investors own 78.79% of the company’s stock.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
VNDA)' title='Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)' />
